Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry
研究概览
简要总结
Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.
The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function.
In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •women who had preeclampsia and women who did not have preeclampsia
- •12 weeks to 5 years postpartum
- •18-45 years old
排除标准
- •history of hypertension or metabolic disease before pregnancy
- •history of gestational diabetes or gestational hypertension
- •skin diseases
- •current tobacco use
- •current antihypertensive medication
- •statin or other cholesterol-lowering medication
- •currently pregnant or planning to become pregnant
- •body mass index less than <18.5 or >30 kg/m2
- •allergy to materials used during the experiment.(e.g. latex),
- •known allergy to study drugs
研究组 & 干预措施
History of a preeclampsia
Women who had preeclampsia in their most recent pregnancy
干预措施: Compound 21 (Drug)
History of a preeclampsia
Women who had preeclampsia in their most recent pregnancy
干预措施: Angiotensin II (Drug)
History of a healthy pregnancy
Women who had an uncomplicated pregnancy
干预措施: Compound 21 (Drug)
History of a healthy pregnancy
Women who had an uncomplicated pregnancy
干预措施: Angiotensin II (Drug)
结局指标
主要结局
Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry
时间窗: at the study visit, an average of 4 hours
cutaneous vascular vasodilator responses to compound 21 perfusion in lactated Ringer's and losartan treated microdialysis sites
Change in microvascular ang II-mediated constriction response measured by laser-Doppler flowmetry
时间窗: at the study visit, an average of 4 hours
cutaneous vascular vasoconstrictor responses to angiotensin II perfusion in lactated Ringer's and PD-123319 treated microdialysis sites
次要结局
未报告次要终点
研究者
Anna Stanhewicz, PhD
Assistant Professor
University of Iowa
